[ad_1]
NEW YORK, December 20, 2018 / PRNewswire / – INTRODUCTION
The success of the Human Genome project has led to the generation of large volumes of genomic data, widely used in biotechnology and medical research. In addition, advances in high-throughput gene sequencing technologies have enabled scientists to accelerate the genome sequencing process and also achieve significant cost benefits. In fact, it is estimated that by 2025 about 15% of the world's population will have sequenced their genomes, resulting in the generation of several zettabytes of data. However, at the moment, there are not many reliable and secure data management resources that offer secure storage, uninterrupted information exchange and a reliable transaction platform for large volumes of genomic and clinical data. Therefore, at this stage, it has become important to develop and establish the tools and technologies needed to effectively contribute to the processing and analysis of the above information and make it readily accessible to physicians, scientists, pharmaceutical companies and other interested parties.
Read the full report: https://www.reportlinker.com/p05663441
Blockchain technology has emerged as a viable option for storing / exchanging genomic data. The decentralized information management model used in blockchains has shown significant advantages in the banking and industry sector. Furthermore, cryptocurrencies, which are based on blockchain technology, are considered a powerful tool for peer-to-peer transactions without involving third parties to track the exchange. In the field of genomics, blockchain can act as a reliable means to carry out transactions between data owners and data users (research groups / pharmaceutical companies). In addition, these platforms allow easy access to genomic data sets, thus significantly improving the process of acquiring information for research studies related to personalized drugs / therapies. As a result, many companies have taken steps to promote the use of blockchain technology for managing genomic data. Indeed, the growing importance of blockchain for the management of genetic information and its use in health decision making is also evident in the number of tweets (~ 1,750) published on the social media platform, Twitter, in recent years. In recent years, recent activities in this area, such as the creation of strategic partnerships (involving pharmaceutical actors and competent government bodies) and investments from venture capital / other stakeholders, indicate that the concept of using blockchain storage platforms and the management of genetic information is gaining traction in the health sector. We believe that these efforts can foster the overall growth of this market in the coming years.
REPORTING REPORT
The report "Blockchain in Genomic Data: Market Landscape and Competitive Insights, 2018-2030" presents a large study on the actors in the sector that offer blockchain platforms for the storage and management of genomic data.
Among other elements, the report presents:
• An overview of the current state of the market compared to companies providing blockchain platforms, along with information on the year of establishment, geographic location, company size, type of business model used, types of services offered to data owners and users of data companies / research institutes), proprietary blockchain platforms and token utilities and end users (pharmaceutical companies, research institutes, genomic data providers (patients and healthy individuals), developers of software and insurers).
• Tabulated profiles of all players engaged in this field, with a brief overview of the company, and details on financing (if available), the types of service offered, proprietary blockchain platforms and utility tokens, important historical milestones, information on partnerships (if available), recent development (s) and future roadmaps / plans (if available).
• An analysis of prevailing and emerging trends related to this domain, represented on the social media platform, Twitter, highlighting the most frequently discussed utility tokens, active players and influential authors. It includes an in-depth analysis of sentiment, which summarizes the impact / influence of various tweets published on the platform.
• A comparative analysis of the needs of different stakeholders (pharmaceutical companies, research institutes, patients, healthy individuals, insurers and government agencies) in this sector.
• A detailed analysis that highlights the various business models and the go-to-market strategies adopted by the companies involved in this space. It presents details on the various channels adopted / adopted by companies to raise awareness and promote the use of their proprietary products / services.
• An informative report on the bubbles, which highlights the market capitalization of utility tokens of various companies engaged in this sector, on the basis of the maximum total offer, of the circulating offer and of the symbolic price .
• A list of cases of recent use of blockchain platforms by pharmaceutical companies, highlighting the ways in which these tools / services have been used to manage and analyze genomic data.
• An in-depth analysis of the opportunities, with an estimate of the size of the existing market; based on multiple parameters, we have also provided an informed estimate of potential growth opportunities for companies engaged in this sector over the period 2018-2030.
• Analysis of various recent developments / trends regarding companies offering blockchain platforms for genomic data management, offering insights on [A] cases where companies have raised funds to support their respective initiatives, [B] partnerships and collaborations established in the sector, [C] other initiatives undertaken by different companies, [D] recent global events (summits, conferences and annual meetings), and [E] opinions expressed / opinions of selected opinion leaders / experts in the field on social media platforms, such as YouTube.
The opinions and insights presented in this study were also influenced by discussions with various stakeholders in this field. The report presents detailed transcripts of the interviews held with the following people:
• David Koepsell (Chief Executive Officer, EncrypGen)
• Jake Dreier (Director of growth and operations, SimplyVital Health)
• Aldo de Pape (Chief Executive Officer, Genomes.io) e Louis Gooden (Analyst, Genomes.io)
All real figures were collected and analyzed by publicly available information forums and primary research discussions. The financial data mentioned in this report are in USD unless otherwise specified.
RESEARCH METHODOLOGY
The research, analysis and analysis presented in this report are supported by a deep understanding of the information gathered from both secondary and primary sources. For all our projects, we conduct interviews with experts in the area (universities, industry and other associations) to solicit their opinions on emerging trends in the market. This is mainly useful for us to get our opinion on how the market will evolve between different regions and technology segments. Wherever possible, the available data has been verified for accuracy by multiple sources of information.
Secondary sources of information include:
• Annual report
• Presentations for investors
• SEC documents
• Industry databases
• News from company websites
• Government policy documents
• The opinions of industry analysts
While the focus has been on forecasting the market until 2030, the report also provides our independent opinion on various emerging non-commercial trends in the sector. This opinion is based exclusively on our knowledge, research and understanding of the relevant market collected from various secondary and primary information sources.
CHAPTER OUTLINES
Chapter 2 is an executive summary of the information acquired in our research. It offers a high-level view of the likely evolution of blockchain technology in the market for managing short-term and medium-term genomics data.
Chapter 3 is an introductory chapter that provides a brief overview of the concept of blockchain technology and its applications in various industries, with a detailed discussion of applications and challenges related to the use of blockchain technology in the healthcare sector. The chapter includes a discussion on historical evolution in the area of genetic sequencing and genetic testing and provides information on the growing importance of sharing / storing / analyzing genomic information through blockchain platforms. In addition, it presents a brief overview of cryptocurrencies and utility tokens, the process of token distribution events, and the role of compression tools for the analysis of a huge volume of genomic data. The chapter also highlights the various advantages and limitations associated with the use of blockchain platforms for the management / analysis of genomic data.
Chapter 4 includes a comprehensive analysis of the market landscape of companies offering blockchain platforms for the storage and management of genomic data. The chapter presents the analysis of these actors on the basis of their year of establishment, geographical location, company size, type of business model used, types of services offered (such as protection / conservation of genomic data, sequencing complete genomics, genetic counseling, genomic data analysis and others), proprietary blockchain platforms and utility tokens and end users (pharmaceutical companies, research institutes, genomic data providers (patients and healthy individuals), software developers and insurers.
Chapter 5 provides the tabulated profiles of all players involved in this field. Each profile contains details on the company's headquarters, the year of incorporation, the number of employees, key executives, funding (if available), types of service offered, proprietary blockchain platforms and utility tokens, stones important milestones, information on members. (if available), recent development (s) and future roadmaps / plans (if available).
Chapter 6 provides insights on the popularity of blockchain platforms, related to the storage and management of genomic data, on the social media platform, Twitter. The section highlights the quarterly distribution of tweets published in the period January 2015-August 2018and the most significant events responsible for increasing the volume of tweets every year. In addition, the chapter shows the most frequently mentioned keywords, most talked about utility tokens and active players, on the social media platform. Illustrates the most prolific contributors and presents a bubble analysis of the most influential contributors related to this domain on Twitter. The chapter also presents an in-depth analysis of sentiment, which summarizes the impact / influence of various tweets published on the platform.
Chapter 7 presents information on the needs of different stakeholders (pharmaceutical companies, research institutes, patients, healthy individuals, insurers and government agencies) in this area. The chapter qualitatively assesses the needs of each stakeholder group and the relative importance of their expectations within this domain.
Chapter 8 presents a detailed case study highlighting the go-to-market strategies adopted by companies engaged in this space. It presents in-depth information on important marketing strategies, such as inbound marketing through social media platforms and online / paper media, promotional activities through official websites and business models used by various players on the market.
Chapter 9 provides an in-depth analysis of the bubbles, highlighting the market capitalization of the companies involved in this domain, based on their proprietary token utilities. For the purposes of this analysis, we took into consideration several relevant parameters, including the total maximum bid, circulation provision and the symbolic price (in USD) of each of the aforementioned utility tokens.
Chapter 10 provides a comprehensive list of recent use of blockchain platforms by pharmaceutical companies, highlighting the ways in which these tools / services have been used to manage and analyze genomic data. Furthermore, the chapter presents an in-depth analysis of the opportunities, with an estimate of the size of the existing market; based on multiple parameters, we have provided an informed estimate of potential growth opportunities for companies engaged in this sector over the period 2018-2030.
Chapter 11 highlights a detailed assessment of the various recent developments / trends in companies offering blockchain platforms for managing genomic data. This analysis presented in this chapter focused on understanding the applications and challenges associated with the use of blockchain platforms for genomic data management and future opportunities for these business models in the healthcare sector. The analysis offers insights on [A] cases where companies have raised funds to support their respective initiatives, [B] partnerships and collaborations established in the sector, [C] other initiatives undertaken by different companies, [D] recent global events (summits, conferences and annual meetings), and [E] opinions expressed / opinions of selected opinion leaders / experts in the field on social media platforms, such as YouTube.
Chapter 12 is a collection of executive insights of the discussions that took place with the main stakeholders in this market. The chapter provides a brief overview of the companies and details of the interviews held David Koepsell (Chief Executive Officer, EncrypGen), Jake Dreier (Director of Growth and Operations, SimplyVital Health) e Aldo de Pape (Chief Executive Officer, Genomes.io) e Louis Gooden (Analyst, Genomes.io).
Chapter 13 is an appendix that provides tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix that contains the list of companies and organizations mentioned in the report.
MAIN EXAMPLES
1. The current market landscape is relatively niche with a limited number of companies offering blockchain platforms for managing genomic data. Of the total number of players involved, more than 35% are based in North America, mainly in the United States. Examples of players based in this region include (in alphabetical order, no specific selection criteria) EncrypGen, GnoMine, LunaDNA and Nebula Genomics. It is worth pointing out that companies are also based in developing regions, such as Brazil, India, Israel, Russia, Singapore is South Korea.
2. Most companies (86%) are engaged in providing services mainly to pharmaceutical operators and research institutes. In addition, companies also offer genomic data management via blockchain platforms to other interested parties such as data owners, software developers and insurers.
3. All companies involved in this sector offer genomic data sharing / transfer services to data owners and data buyers. In addition, companies claim to offer services such as the storage of genomic data (87%), anonymity of data (87%), incentives for sharing genomic data (87%), complete sequencing of the genome (53%) and genetic counseling (27%), exclusively to data owners. In addition, the services offered to data buyers include access to genomic data sets and analysis of genomic data.
4. An analysis of over 1,750 tweets on social media platforms and opinions expressed by industry experts highlight unaddressed concerns related to the management of genomic data; these include privacy issues, unsafe transactions and lack of security / reliability related to stored genomic data. It is worth mentioning that these challenges can be addressed through the exchange of data on blockchain platforms. A full tweet analysis showed that 85% was positive, suggesting that, at this stage, stakeholders are optimistic about the potential future of blockchain genomic data management platforms.
5. In order to improve the adoption of blockchain platforms in the management of genomic data, industry stakeholders are exploring a variety of innovative marketing strategies. The most popular marketing strategies that are implemented include the use of social media platforms to spread awareness about blockchain platforms, online media and growing participation in global events, such as conferences, to achieve the required visibility on the market.
6. The overall capitalization of the currency market is currently estimated around 400 million US dollars 750 million, based on the total maximum bid, the circulation offer and the price (in USD) of the utility tokens of various companies engaged in this sector. Considering that such platforms are readily adopted in the health sector, the above value is expected to increase significantly over the long term.
7. Overall, the market for managing genomic data using blockchain platforms should increase at an annualized rate of 43.5% between 2018 and 2030. While the current opportunity is higher for applications related to the development of personalized medicines, its scope in other applications areas (such as advanced genetic analysis services and identification of genotypic markers to allow better diagnosis) are expected to grow at a relatively faster rate during the forecast period.
Read the full report: https://www.reportlinker.com/p05663441
Information on Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can get all the market research you need, instantly, in one place.
__________________________
Contact Clare: [email protected]
United States: (339) -368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related links
http://www.reportlinker.com
